Tallarna and ABB Strengthen Strategic Partnership With Investment Deal
22.11.2022 14:00:00 EET | Business Wire | Press release
Tallarna, an award-winning climate tech company for the built environment, today announced that it has closed a strategic partnership and minority investment deal with ABB, a technology leader in electrification and automation. This signals a joint commitment to a software-led, risk-managed approach to accelerate net zero.
ABB’s solutions connect engineering know-how and software to optimise how things are manufactured, moved, powered, and operated. Building on more than 130 years of excellence, the company's expertise will be indispensable for the next stage of Tallarna’s growth.
Since launching four years ago, Tallarna has built a talented and loyal team, and has experienced wide-scale traction across the real estate sector – encompassing social housing providers, energy infrastructure developers, and green lenders. With ABB’s backing, the company’s scope will be extended to Energy Service Companies (ESCOs) serving commercial and industrial organisations.
Tallarna’s AI platform, KESTREL, makes decarbonisation projects a reality by aligning what can be achieved from an engineering perspective with what can be insured and funded. By finding the commonality between decision makers, the company opens the door to a new era of scalability. Tallarna’s software is integrated with the related underwriting processes of AmTrust Financial Services, a global specialty property and casualty insurer, who is also an existing investor. Together, the companies have created a unique Energy Savings Insurance product which enables customers to access project investors integrated into Tallarna’s platform.
As the climate and energy crisis grows, decision makers need the right tools to lower their emissions and operating costs. ABB’s deep knowledge of equipment performance and innovative electrification technology will enhance Tallarna’s existing capabilities. Coupling ABB products with performance insurance will give customers the confidence to action their sustainability journey.
“Never before has there been such a need for clear insights into decarbonisation possibilities and how to deliver them. Cross-industry collaboration is key to ensuring a sustainable future for all. As such, we are delighted to be working more closely with the Tallarna team and to support their launch in the ESCO market,” Giuseppe Casagrande, Global Digital Leader at ABB Electrification, Smart Power Division.
“As a company, our mission is to empower sustainability in all its forms – environmental, economic, and social. ABB shares this perspective, and we are excited to work with them on addressing the awareness, confidence, and execution gap facing customers,” Tim Meanock, CEO at Tallarna.
ABB’s investment and partnership will guide Tallarna in growing the market - taking decarbonisation to new heights for commercial, industrial, and energy infrastructure providers.
ESCO customers will benefit in 4 key ways:
-
Lower the barrier to entry for decarbonisation projects
Tallarna understands customers’ decarbonisation options using minimal data and, initially, without the need for connected devices. This capability will be augmented with ABB’s knowledge of innovative energy optimisation solutions in industrial settings.
-
Point a route to scale for customer projects
KESTREL translates engineering challenges into risk metrics and is used to underwrite and distribute Energy Savings Insurance. By adding ABB’s insights to this modelling, the companies will further mitigate risk while lowering costs and carbon emissions. Removing the performance risk from ESCOs and building owners encourages greater project scope and facilitates a service model, driving a route to scale.
-
Enable the market to move faster by overcoming barriers to execution
Guaranteed energy outputs can be financed, with the realised bill savings repaying the project costs. Not only does this deliver new funding sources for developers, but it creates financial assets for Tallarna’s panel of project investors. This provides a key mechanism for execution.
-
Ensure security of technology supply and performance
Tallarna can specify suitable technology products at the project exploration stage. These include offerings from a range of providers, including ABB. Technology is pre-validated for insurance and finance terms, and can be onboarded to provide security of supply, performance, and pricing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005392/en/
Contact information
Michelle Taute
Senior Strategic Sustainability Lead
press@tallarna.com
+44 7771786102
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
